Literature DB >> 15620719

PD98059 and U0126 activate AMP-activated protein kinase by increasing the cellular AMP:ATP ratio and not via inhibition of the MAP kinase pathway.

Kanchana Dokladda1, Kevin A Green, David A Pan, D Grahame Hardie.   

Abstract

The MAP kinase pathway inhibitor U0126 caused phosphorylation and activation of AMP-activated protein kinase (AMPK) and increased phosphorylation of its downstream target acetyl-CoA carboxylase, in HEK293 cells. This effect only occurred in cells expressing the upstream kinase, LKB1. Of two other widely used MAP kinase pathway inhibitors not closely related in structure to U0126, PD98059 also activated AMPK but PD184352 did not. U0126 and PD98059, but not PD184352, also increased the cellular ADP:ATP and AMP:ATP ratios, accounting for their ability to activate AMPK. These results suggest the need for caution in interpreting experiments conducted using U0126 and PD98059.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15620719     DOI: 10.1016/j.febslet.2004.11.084

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  22 in total

1.  A unique model for SDH-deficient GIST: an endocrine-related cancer.

Authors:  James F Powers; Brent Cochran; James D Baleja; Hadley D Sikes; Xue Zhang; Inna Lomakin; Troy Langford; Kassi Taylor Stein; Arthur S Tischler
Journal:  Endocr Relat Cancer       Date:  2018-07-02       Impact factor: 5.678

2.  A metabolic perturbation by U0126 identifies a role for glutamine in resveratrol-induced cell death.

Authors:  Michael R Freeman; Jayoung Kim; Michael P Lisanti; Dolores Di Vizio
Journal:  Cancer Biol Ther       Date:  2011-12-01       Impact factor: 4.742

3.  Acute mitochondrial inhibition by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) 1/2 inhibitors regulates proliferation.

Authors:  Maureen O Ripple; Namjoon Kim; Roger Springett
Journal:  J Biol Chem       Date:  2012-12-12       Impact factor: 5.157

4.  Identification of an intracellular metabolic signature impairing beta cell function in the rat beta cell line INS-1E and human islets.

Authors:  I Goehring; N S Sauter; G Catchpole; A Assmann; L Shu; K S Zien; M Moehlig; A F H Pfeiffer; J Oberholzer; L Willmitzer; J Spranger; K Maedler
Journal:  Diabetologia       Date:  2011-07-28       Impact factor: 10.122

5.  A trifluoromethyl analog of verbenachalcone promotes neurite outgrowth and cell proliferation of NeuroScreen-1 cells.

Authors:  Susan Yeyeodu; Nailya Gilyazova; Eun Young Huh; Srinivasa R Dandepally; Carla Oldham; Alfred Williams; Gordon Ibeanu
Journal:  Cell Mol Neurobiol       Date:  2010-09-17       Impact factor: 5.046

6.  The effect of MEK1/2 inhibitors on cisplatin-induced acute kidney injury (AKI) and cancer growth in mice.

Authors:  Carolyn N Brown; Daniel J Atwood; Deepak Pokhrel; Kameswaran Ravichandran; Sara J Holditch; Sanskriti Saxena; Makoto Miyazaki; Raphael Nemenoff; Mary C M Weiser-Evans; Danica Galesic Ljubanovic; Melanie S Joy; Charles L Edelstein
Journal:  Cell Signal       Date:  2020-03-16       Impact factor: 4.315

Review 7.  Diphosphoinositol polyphosphates: metabolic messengers?

Authors:  Stephen B Shears
Journal:  Mol Pharmacol       Date:  2009-05-13       Impact factor: 4.436

8.  Cellular energetic status supervises the synthesis of bis-diphosphoinositol tetrakisphosphate independently of AMP-activated protein kinase.

Authors:  Kuicheon Choi; Elahe Mollapour; Jae H Choi; Stephen B Shears
Journal:  Mol Pharmacol       Date:  2008-05-06       Impact factor: 4.436

9.  Off-target effects of MEK inhibitors.

Authors:  Eric M Wauson; Marcy L Guerra; Barbara Barylko; Joseph P Albanesi; Melanie H Cobb
Journal:  Biochemistry       Date:  2013-07-22       Impact factor: 3.162

10.  Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells.

Authors:  Tao Pang; Zhen-Shan Zhang; Min Gu; Bei-Ying Qiu; Li-Fang Yu; Peng-Rong Cao; Wei Shao; Ming-Bo Su; Jing-Ya Li; Fa-Jun Nan; Jia Li
Journal:  J Biol Chem       Date:  2008-03-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.